The no-smoking policy will go into effect once Reynolds builds indoor smoking areas for those still wanting to light up indoors, a spokesperson said.» Read More
WASHINGTON, Oct 29- Cigarette maker Reynolds American's proposal to buy smaller rival Lorillard Inc presents antitrust regulators with a conundrum: Their mandate is to prevent higher prices because of mergers, but U.S. public policy aims to make cigarettes more expensive to discourage smoking. Reynolds, the No. 2 U.S. cigarette maker, said in July it would buy No. 3...
RICHMOND, Va.— Newport maker Lorillard Inc.' s third-quarter profit jumped 12 percent as higher cigarette prices helped offset a decline in the number of cigarettes it sold. Despite the drop in sales, Lorillard, which bought Blu in 2012 for $135 million, said the brand continued to hold a nearly 30 percent share of the U.S. retail market. Last year, Lorillard bought a...
RICHMOND, Va.— Camel cigarette maker Reynolds American Inc. is snuffing out smoking in its offices and buildings. The no-smoking policy will go into effect once Reynolds builds indoor smoking areas for those still wanting to light up indoors, spokesman David Howard said. First released in the mid-1990s, Eclipse is in limited distribution and one of the...
NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. The Coca-Cola Co., down $2.61 to $40.68. Chipotle Mexican Grill Inc., down $45.48 to $607.55.
The Winston-Salem, North Carolina- based company said its profit rose to $467 million, or 88 cents per share, for the quarter which ended Sept. 30, up from $457 million, or 84 cents per share, in the same quarter last year. Reynolds' adjusted earnings of 95 cents per share beat expectations for 91 cents per share, according to Zacks Investment Research.
RICHMOND, Va.— The CEO of Newport cigarette maker Lorillard Inc. is set to receive more than $44 million following the planned $25 billion merger with Reynolds American Inc., regulatory filings show. Murray Kessler is one of several Lorillard executives to receive compensation if they're terminated after the deal closes, according to a filing with the...
President and chief commercial officer, R.J. Reynolds Tobacco
LONDON/ NEW YORK, Sept 12- As electronic cigarettes flew off shelves on both sides of the Atlantic in recent years, investors flocked to a business some hope will be the future for tobacco.
Sept 3- Lorillard Inc said two of its e-cigarette subsidiaries sued Zippo Manufacturing Co in the United Kingdom to protect itself from Zippo's claims of trademark infringement regarding the blu brand of e-cigarettes.
The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.
CHICAGO, Aug 25- Electronic cigarettes may be more tempting to non-smoking youths than conventional cigarettes, and once young people have tried e-cigarettes they are more inclined to give regular cigarettes a try, U.S. researchers said on Monday.
Aug 18- A German court has ordered a subsidiary of U.S. tobacco giant Lorillard Inc to stop selling the popular blu e-cigarettes in that country, citing trademark confusion with lighter and fuel products sold by Zippo Manufacturing Co..
LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.
All three U.S. laboratories established to fight major public health threats say they are standing by to scale up a treatment for Ebola.
NEW YORK/ WASHINGTON, Aug 9- All three U.S. facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.
The M&A wave could be a harbinger of a booming economy...or a collection of last-minute attempts to beat higher debt rates. NYT reports.
NEW YORK, Aug 6- Drugmakers' use of the tobacco plant as a fast and cheap way to produce novel biotechnology treatments is gaining global attention because of its role in an experimental Ebola therapy.
Companies across industry groups—from food to technology to health care—are raising costs for the consumer.
Susan Cameron is confident regulators will allow the tobacco giant to acquire Lorillard for $24.7 billion.
A cult following is likely to grow as "vaping" becomes more fashionable and more stores, such as Walmart, carry the battery-powered metal tubes in a wide range of colors.